Positive CHMP Opinion for Palforzia® in Peanut Allergy Treatment
Stallergenes Greer, a renowned biopharmaceutical company specializing in allergen immunotherapy (AIT), has recently announced a pivotal decision regarding its product, Palforzia®. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a favorable opinion extending the indication of Palforzia® to include toddlers aged 1 to 3 years who are diagnosed with peanut allergies. If the European Commission grants this extension, Palforzia® will become the first approved oral immunotherapy treatment for young children with confirmed peanut allergies in the European Union.
Understanding Palforzia® and Its Treatment Protocol
Palforzia® is designed to facilitate the gradual desensitization of the immune system to peanuts by increasing the body’s tolerance to small amounts of peanut protein. This is achieved through a carefully controlled process involving supervised initial dose escalation, as well as ongoing up-dosing and maintenance phases. The new indication aims to initiate treatment at an earlier stage, providing many young children and their families with the means to significantly reduce the risk of severe allergic reactions from accidental peanut exposure.
Significance of the CHMP Recommendation
The recommendation from the CHMP is currently under review by the European Commission, which holds the authority to grant central marketing authorizations for medicinal products in the EU. If approved, this marketing authorization will apply across all 27 EU member states and three EEA states. Moreover, it’s notable that the U.S. Food and Drug Administration (FDA) has already approved the extension of Palforzia® for use in toddlers as of mid-2024.
Research Behind the Regulatory Submission
The basis for this regulatory submission stems from the findings of the Phase 3 POSEIDON study, an international randomized study, which was published in a reputable medical journal in 2023. This extensive research demonstrated both the efficacy and safety of Palforzia® in toddlers with peanut allergies, fulfilling all predefined efficacy endpoints and showcasing a robust safety profile.
Expert Insights on the Development
Elena Rizova, the Chief Medical Officer at Stallergenes Greer, expressed her enthusiasm regarding the CHMP recommendation, highlighting its importance for young children suffering from peanut allergies and their families. She noted that this achievement is a testament to Stallergenes Greer’s commitment to innovative solutions for allergy sufferers.
Comprehensive Offerings by Stallergenes Greer
As Stallergenes Greer pursues its mission to expand access to Palforzia®, the company is focused on developing solutions that cater to the diverse needs of patients. Their portfolio encompasses a wide range of treatments, including oral immunotherapy for food allergies and both tablet and liquid sublingual solutions for respiratory and insect venom allergies. With such innovations, Stallergenes Greer is at the forefront of personalized allergen immunotherapy.
About Palforzia®
Palforzia® is currently approved by the European Medicines Agency for patients aged 4 to 17 years diagnosed with peanut allergies and can be continued for patients over the age of 18. The treatment aims to be used in conjunction with a strict peanut-avoidant diet to maximize effectiveness and minimize risks. In addition, the FDA has approved Palforzia® for mitigating allergic reactions in children aged 1-17 years, specifically focusing on accidental exposure to peanut allergens.
Poseidon Phase 3 Clinical Study
The POSEIDON study, with clinical trial number NCT03736447, set out to rigorously evaluate the efficacy and safety of Palforzia® among peanut-allergic children in North America and Europe. Conducted as a double-blind, placebo-controlled trial, the study involved a careful enrollment process based on specific criteria. Participants were monitored through a dose-escalation phase lasting around 22 weeks, leading to a maintenance phase where they continued receiving their doses.
About Stallergenes Greer International AG
Stallergenes Greer International AG, with its headquarters in Baar, Switzerland, is a global leader in the allergy treatment sphere. The company is dedicated to diagnosing and managing a wide range of allergies through the development and commercialization of advanced allergen immunotherapy products and services. With its global presence and innovation-driven approach, Stallergenes Greer continues to strive for significant advancements in allergy therapeutic solutions.
Frequently Asked Questions
What is Palforzia® used for?
Palforzia® is used to treat peanut allergies in children, helping to desensitize them to peanut exposure.
What age group is Palforzia® approved for?
Palforzia® is approved for children aged 1 to 17 years for the treatment of peanut allergies.
Who developed Palforzia®?
Palforzia® was developed by Stallergenes Greer, a company focused on allergy immunotherapy solutions.
What is the POSEIDON study?
The POSEIDON study is a Phase 3 clinical trial assessing the safety and efficacy of Palforzia® in young children with peanut allergies.
Where is Stallergenes Greer located?
Stallergenes Greer is headquartered in Baar, Switzerland and operates globally in the field of allergy treatment.
